Pyrophosphoric Acid

Pyrophosphoric Acid

SCHEMBL438388

O=P(O)(O)OP(=O)(O)O.[Fe]

nearest known ligand 0.91

Full drug profile on Sugi Atlas →

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
FDPS P14324 1/20 0.91
BLM P54132 1/20 0.91
TDP1 Q9NUW8 1/20 0.91
CA4 P22748 1/20 0.37
CA2 P00918 1/20 0.36
INPPL1 O15357 2/20 0.35
INPP5A Q14642 2/20 0.35
SMPD1 P17405 1/20 0.35
INPP5B P32019 1/20 0.35
BTN3A1 O00481 2/20 0.35
ITPR3 Q14573 3/20 0.33
SLC34A1 Q06495 1/20 0.33
ITPR2 Q14571 1/20 0.33
ITPR1 Q14643 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Pyrophosphoric Acid SCHEMBL5575709 1.00 FDPS (0.91) FDPSBLMTDP1CA4CA2
Pyrophosphoric Acid SCHEMBL5083035 1.00 FDPS (0.91) FDPSBLMTDP1CA4CA2
Pyrophosphoric Acid SCHEMBL3175481 0.96 FDPS (0.83) FDPSBLMTDP1CA4CA2
Pyrophosphoric Acid SCHEMBL17416228 0.96 FDPS (0.83) FDPSBLMTDP1CA4CA2
Pyrophosphoric Acid SCHEMBL16529918 0.96 FDPS (0.83) FDPSBLMTDP1CA4CA2
Pyrophosphoric Acid SCHEMBL19742227 0.96 FDPS (0.83) FDPSBLMTDP1CA4CA2
Pyrophosphoric Acid SCHEMBL16529917 0.96 FDPS (0.83) FDPSBLMTDP1CA4CA2
Pyrophosphoric Acid SCHEMBL9719940 0.96 FDPS (0.83) FDPSBLMTDP1CA4CA2
Pyrophosphoric Acid SCHEMBL597629 0.96 FDPS (0.83) FDPSBLMTDP1CA4CA2
Pyrophosphoric Acid SCHEMBL9799845 0.96 FDPS (0.83) FDPSBLMTDP1CA4CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1440 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12636313-B2 Nutraceutical or pharmaceutical composition comprising iron pyrophosphate for treating and/or preventing iron deficiency conditions or diseases Neilos S.r.l. (IT) 2026-05-26 US claimed
US-12630885-B2 Viability detection and quantification assay of waterborne pathogens by enrichment PHIGENICS, LLC 2026-05-19 US claimed
US-20260114488-A1 COMPOSITIONS AND METHODS FOR PROMOTING DEVELOPMENT OF INFANT BOBBIE BABY INC (US) 2026-04-30 US claimed
EP-4728878-A1 NUTRITIONAL COMPOSITION FOR PREGNANT WOMEN AND PREPARATION METHOD THEREFOR Hainan Tianzhuang Nutrition Engineering Co., Ltd (CN) 2026-04-22 EP claimed
US-20260071340-A1 CATALYST FOR WATER ELECTROLYSIS ELECTRODE, METHOD FOR PREPARING THE CATALYST, AND WATER ELECTROLYSIS ELECTRODE SK INNOVATION CO LTD (KR) 2026-03-12 US claimed
EP-4707430-A2 CATALYST FOR WATER ELECTROLYSIS ELECTRODE, PREPARING METHOD OF CATALYST FOR WATER ELECTROLYSIS ELECTRODE, WATER ELECTROLYSIS ELECTRODE, AND WATER ELECTROLYSIS SYSTEM SK Innovation Co., Ltd. (KR) 2026-03-11 EP claimed
US-20260014404-A1 LONG-TERM FIRE RETARDANT WITH CORROSION INHIBITORS AND METHODS FOR MAKING AND USING SAME PERIMETER SOLUTIONS, LP (US) 2026-01-15 US claimed
EP-4676451-A1 COMPOSITION COMPRISING MEDIUM-CHAIN TRIGLYCERIDES, OMEGA-3 AND CHOLINE FOR USE IN A METHOD OF TREATMENT OF COGNITIVE DECLINE AND DEMENTIA Global Pharmacies Partner S.R.L. in Forma Abbreviata G.P.P. S.R.L. (IT) 2026-01-14 EP claimed
US-12503789-B2 Die-casting metal part-polymer resin composite and method for preparing same PLASTAL CO., LTD. (KR) 2025-12-23 US claimed
EP-4661880-A1 NEW IRON AND SODIUM PYROPHOSPHATE ORAL COMPOSITIONS, PROCESS FOR THEIR PREPARATION AND THEIR USE IN IRON DEFICIENCY CONDITIONS Pharmanutra S.p.A. (IT) 2025-12-17 EP claimed
EP-0029595-A1 An improved high solids coating composition of a low molecular weight glycidyl acrylic polymer and an alkylated melamine cross-linking agent, and a substrate coated therewith E.I. DU PONT DE NEMOURS AND COMPANY (US) 1981-06-03 EP claimed
EP-0029598-A1 An improved high solids coating composition of a low molecular weight acrylic polymer and a polyisocyanate cross-linking agent, and a substrate coated therewith E.I. DU PONT DE NEMOURS AND COMPANY (US) 1981-06-03 EP claimed
EP-0029597-A1 An aqueous thermosetting acrylic coating composition, articles coated therewith, and process for preparing said coated articles E.I. DU PONT DE NEMOURS AND COMPANY (US) 1981-06-03 EP claimed
US-4262060-A ELECTRODEPOSITION OF BLACK COATING INCLUDING TERNARY ALLOY ON METALLIC SUBSTRATE TOKYO SHIBAURA DENKI KABUSHIKI KAISHA (JP) 1981-04-14 US claimed
US-4255308-A A DISPERSION COMPRISING A BINDER OF A METHYL METHACRYLATE POLYMER, A DISPERSANT OF AN ACRYLIC TERPOLYMER, AND A GRAFT POLYMER OF THE TWO; FINISHES FOR CARS AND TRUCKS E. I. DU PONT DE NEMOURS AND COMPANY (US) 1981-03-10 US claimed
WO-1981000233-A1 CLEAR COAT/COLOR COAT FINISH CONTAINING AN ULTRAVIOLET LIGHT STABILIZER DU PONT 1981-02-05 WO claimed
US-4208465-A ACRYLIC POLYMERS; WEATHERABLE ENAMELS FOR AUTOMOBILES E. I. DU PONT DE NEMOURS AND COMPANY (US) 1980-06-17 US claimed
US-4120835-A Thermosetting acrylic enamel containing iron pyrophosphate E. I. DU PONT DE NEMOURS AND COMPANY (US) 1978-10-17 US claimed
US-4113499-A ALKYL SILICATE, WATER, HYDROCHLORIC ACID, PHOSPHATE, SURFACTANT, REFRACTORY FILLER IVANOV VALENTIN NIKOLAEVICH 1978-09-12 US claimed
US-4052323-A HIGH-TEMPERATURE LUBRICANT FOR THE HOT-WORKING OF METALS LONZA, LTD. (CH) 1977-10-04 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260071340-A1 CATALYST FOR WATER ELECTROLYSIS ELECTRODE, METHOD FOR PREPARING THE CATALYST, AND WATER ELECTROLYSIS ELECTRODE SLC9A2, FECH, SLC9A1 FDPS 4037/4885BLM 3928/4885TDP1 3134/4885
US-12636313-B2 Nutraceutical or pharmaceutical composition comprising iron pyrophosphate for treating and/or preventing iron deficiency conditions or diseases FECH, SLC40A1, SLC25A20 FDPS 210/4885BLM 2783/4885TDP1 4353/4885
US-20260014404-A1 LONG-TERM FIRE RETARDANT WITH CORROSION INHIBITORS AND METHODS FOR MAKING AND USING SAME SLC6A12, SLC11A2, KCNN1 FDPS 2024/4885BLM 3080/4885TDP1 831/4885
US-12630885-B2 Viability detection and quantification assay of waterborne pathogens by enrichment POLL, Q6ZSR9, DNTT FDPS 4319/4885BLM 892/4885TDP1 324/4885
US-20260114488-A1 COMPOSITIONS AND METHODS FOR PROMOTING DEVELOPMENT OF INFANT SLC19A1, MTHFD1, MTHFD2 FDPS 123/4885BLM 4753/4885TDP1 3078/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.